我武生物(300357) - 2024 Q1 - 季度财报

Financial Performance - The company's revenue for Q1 2024 was CNY 216,249,528.11, representing an 18.08% increase compared to CNY 183,139,637.81 in the same period last year[9]. - Net profit attributable to shareholders was CNY 77,207,320.73, a 9.55% increase from CNY 70,478,103.64 year-on-year[9]. - The sales revenue of the product "Dust Mite Drops" was CNY 207,315,100.13, up 15.93% year-on-year, while "Artemisia Pollen Allergen Sublingual Drops" sales increased by 143.68% to CNY 6,480,441.29 due to enhanced marketing efforts in northern markets[21]. - The company's basic earnings per share increased by 9.58% to CNY 0.1475, compared to CNY 0.1346 in the same period last year[9]. - Net profit for the current period was ¥73,915,884.55, representing a 10.73% increase from ¥67,020,356.59 in the previous period[34]. - The company reported a total profit of ¥87,795,621.84, an increase of 17.5% from ¥74,695,305.79 in the previous period[34]. Cash Flow and Assets - The net cash flow from operating activities decreased by 47.84% to CNY 43,771,270.48, down from CNY 83,916,819.04 in the previous year[9]. - Cash flow from operating activities generated a net amount of ¥43,771,270.48, down 47.8% from ¥83,916,819.04 in the prior period[36]. - The total assets at the end of the reporting period were CNY 2,624,140,370.31, a 2.42% increase from CNY 2,562,166,715.87 at the end of the previous year[9]. - The total assets increased to ¥2,624,140,370.31 from ¥2,562,166,715.87, reflecting a growth of approximately 2.43%[44]. - Cash and cash equivalents at the end of the period reached ¥1,195,259,993.17, up from ¥1,171,377,407.31, indicating an increase of about 2.03%[44]. - The net cash flow from investing activities was negative at -¥25,116,886.15, compared to -¥25,985,064.22 in the previous period[49]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 27,422[24]. - Zhejiang Wuwei Management Consulting Co., Ltd. holds 38.86% of shares, totaling 203,454,131 shares[24]. - Hu Gengxi, a natural person, holds 8.35% of shares, totaling 43,698,370 shares[24]. - The National Social Security Fund's 112 combination holds 4.83% of shares, totaling 25,291,122 shares[24]. - The National Social Security Fund's 406 combination holds 3.42% of shares, totaling 17,896,239 shares[24]. - The total number of shares held by the top ten shareholders accounts for a significant portion of the total equity[27]. Other Income and Expenses - Other income increased significantly by 649.12% to CNY 4,944,446.96, primarily due to an increase in government subsidies related to daily activities[22]. - Other income rose significantly to ¥5,706,164.22, compared to ¥761,717.26 in the prior period[32]. - Research and development expenses increased to ¥30,563,652.07, up 25.3% from ¥24,412,999.90 in the previous period[32]. - The company experienced a foreign exchange gain of ¥108.47, compared to a loss of ¥5,957.92 in the previous period[36]. - The company’s investment income showed a loss of ¥363,771.21, a decline from a profit of ¥2,468,267.68 in the previous period[32]. Strategic Initiatives - The company announced a "Quality and Return Dual Improvement" action plan on March 8, 2024, to enhance company quality and investment value[28]. - The company aims to boost investor confidence and market activity in line with government directives[28].